- Enlivex Receives Regulatory Authorization for the Initiation of a Placebo-Controlled Phase I/II Trial Evaluating Allocetra in Up To 46 Patients with Thumb Osteoarthritis
- Enlivex Therapeutics Closes up to $15 Million Registered Direct Offering
- Enlivex Therapeutics Announces up to $15 Million Registered Direct Offering
- Enlivex CEO Issues Letter to Shareholders – Perspectives on Recent Events
- Enlivex Announces Dosing of First Two Patients in its Randomized, Controlled Phase I/II Trial Evaluating Allocetra™ in Patients with Knee Osteoarthritis
- Enlivex Announces Authorization from the Danish Regulatory Agency for the Company’s Randomized, Controlled Phase I/II Trial Evaluating Allocetra in Patients with Knee Osteoarthritis
- Enlivex to Host Webcast on April 12, 2024 at 8:30 a.m. Eastern Time to Discuss Topline Results from Its Phase II Trial Evaluating Allocetra™ In Patients with Sepsis
- Enlivex Announces Topline Results of Its Phase II Trial Evaluating Allocetra™ In Patients With Sepsis
- Enlivex Announces Issuance of New U.S. Patent Covering Allocetra Cells and Their Manufacturing Method
- Enlivex Receives IMOH Regulatory Authorization for the Initiation of a Multi-Country, Randomized, Controlled Phase I/II Trial Evaluating Allocetra in Up To 160 Patients with Moderate to Severe Knee Osteoarthritis
More ▼
Key statistics
On Friday, Enlivex Therapeutics Ltd (ENLV:NAQ) closed at 1.34, 16.52% above the 52 week low of 1.15 set on Apr 15, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 1.44 |
---|---|
High | 1.44 |
Low | 1.18 |
Bid | 1.16 |
Offer | 1.36 |
Previous close | 1.38 |
Average volume | 68.46k |
---|---|
Shares outstanding | 20.66m |
Free float | 18.01m |
P/E (TTM) | -- |
Market cap | 27.89m USD |
EPS (TTM) | -1.56 USD |
Data delayed at least 15 minutes, as of Jun 07 2024 20:59 BST.
More ▼